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ABSTRACT

Caffeine has been propoited to increase endurance exercise time to exhaustion.
However, the effects o f caffeine on high-intensity, intermittent exercise to exhaustion
have not been widely studied. Therefore, the purpose o f this study was to examine the
effect o f caffeine on intermittent, high intensity exercise to exhaustion in individuals with
minimal daily dietary caffeine consumption. Seven male participants, age 26 ± 2 years,
body mass 77 ± 11 kg, and

47 ± 7 ml/kg/miru performed a high-intensity exercise

bout under both caffeine and placebo conditions administered in a counterbalanced,
double blind fashion. Participants cycled at 120% o f peak power output for 60 seconds
followed by 120 seconds o f recovery at 50 Watts. Work/rest cycles continued until
voluntary exhaustion. Blood samples were taken immediately prior to administering
caffeine or placebo beverages, one hour post absorption, and immediately following the
conclusion o f the exercise test No significant difference in time to exhaustion was found
between caffeine and placebo trials (12.5 ± 5.9 vs 12.3 ± 6.6 min), nor did peak blood
lactate concentration differ between trials (11.3 ± l.O vs 11.6 ± 1.9 mM). These results
suggest that caffeine treatment provides no significant improvement in performance time
during intermittent, high-intensity exercise to exhaustion.
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CHAPTER I

INTRODUCTION
Caffeine is the most widely used psychoactive drug in the world (James, 1991).
The most common form o f caffeine consumption is coffee, which accounts for
approximately 54% of caffeine ingestion, with tea accounting for approximately 43%.
The remaining 3% o f caffeine ingestion is in the form o f chocolate or cocoa products, soft
drinks, and medications (Gilbert, 1984). Because caffeine is virtually free o f barriers to
diffusion, it produces many effects including restlessness, increased lipolysis resulting in
a proported glycogen sparing effect, alterations in neuromuscular transmission and
mental acuity. Physiological and psychological alterations in behavior derived from
caffeine consumption, have led to its use by athletes in an attempt to enhance
performance.
While some studies have reported ergogenic benefits from consuming caffeine
(Costill, 1978; Jackman et al., 1996, Trice & Hymes, 1995), other studies fail to show
caffeine related ergogenic benefits (Cadarette et al., 1983, Williams, 1988).
To date, much o f the research concerned with the potential ergogenic benefits of
caffeine has focused on endurance rather than short term exercise. Endurance athletes,
such as triathletes and marathon runners, may find caffeine appealing because it is
reported to alter substrate utilization (Costill et al., 1978; Spriet et al., 1992). Less clear
I

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

2
is the potential benefit for short term higher intensity activities where caffeine may act to
modify neuromuscular transmission. Research findings in each o f these areas have been
inconsistent, with some studies reporting significant benefits while others show
negligible differences between caffeine and control groups (Costill et al., 1992; Powers et
al., 1983).
Currently, very little research has focused on the effects o f caffeine on
performance involving short, intense bouts of exercise, separated by brief periods o f rest.
It is possible that participants in sports such as hockey, tennis, and soccer may derive
benefits fi-om caffeine supplementation prior to competition. These benefits may include
performing at a higher intensity for a longer period of time due to a decrease in the
perception of fatigue, elevated catecholamine levels, or enhanced neuromuscular
transmission. This study proposes to research the effects o f caffeine on short term, highintensity exercise in an effort to further define the role of caffeine in improving
performance.

Limitations
1. Participants for this study were college age males o f average physical characteristics
and physical fitness level. Inference o f data to the population should be done with
caution.

Assumptions
1. Participants gave a maximal effort during the peak aerobic capacity pretest, and both
exercise test protocols.
2. Participants abstained fitjm all caffeine intake for a minimum o f 4 days prior to the
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beginning o f the exercise test and maintained this behavior until the conclusion o f the
test
3. Participants performed a 12 hour abstinence o f food prior to performing the exercise
tests.
4. Peak caffeine levels occur one hour post absorption on an empty stomach.

Statement o f Hypotheses
Null Hypothesis:
Hg: Caffeine will not enhance performance and extend the time to exhaustion during
exercise that is intermittent and o f high intensity.

Alternate Hypothesis:
H,: Caffeine will extend the time to exhaustion during intermittent, high-intensity
exercise.
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CHAPTER 2

LITERATURE REVIEW
Pharmacology
Caffeine is part o f the family methylated xanthines whose structure is based on
the purine ring. Caffeine’s structure is represented by 1,3,7-trimethylxanthine and it’s
most active isomers are theobromine (3,7-dimethylxanthine), theophylline
(1,3-dimethyIxanthine), and paraxanthine (1,7-dimethybcanthine). Caffeine, theobromine
and theophylline are naturally occurring products while paraxanthine is not.
Theophylline appears to convert reversibly between caffeine and theophylline isomers
(Looser et al., 1974; Roberts & Waller, 1979) while theobromine and paraxanthine are
products o f caffeine metabolism (Amaud, 1987). Xanthines are relatively insoluble in
liquids. However, salt compound formation tends to improve xanthine solubility (Powers
& Dodd, 1985).
The pharmacokinetics o f caffeine are unique. Caffeine is virtually free of barriers
to diffusion including the blood-brain barrier (Rail, 1985; Somani, Khana, & Bada,
1980). Plasma caffeine levels begin to increase within 15 minutes after an oral dose, with
peak levels occurring within one to two hours depending on such factors as stomach
contents and whether the caffeine was consumed during an activity or at rest (Axelrod &
Reichenthal, 1953; Rail, 1980). The rate o f caffeine excretion is a function of liver
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metabolism. The half life o f caffeine generally ranges from two to four hours, although
infants and individuals with hepatic abnormalities or impairment tend to show an
increased caffeine half life. Other factors affecting caffeine half life include age, gender,
smoking, and oral contraceptive use (Blanchard & Sawers, 1983; Callahan, Robertson,
Branfinan, McComish, & Yesair, 1983; Yesair, Branfinan, & Callahan, 1984; Parsons &
Neims, 1978).
An integral component o f the pharmacokinetics o f caffeine is dose size. The
effectiveness o f caffeine as an ergogenic aid appears to be largely affected by the size of
the caffeine dose administered. Graham and Spriet (1995) administered doses o f 3,6,
and 9 mg per kilogram body weight to participants who ran at 85% VO,max until
voluntary exhaustion. Endurance was significantly improved over the placebo trial with
the 3 and 6 mg/kg doses but not with the 9 mg/kg dose, suggesting that athletes
attempting to gain performance enhancement via caffeine supplementation need to avoid
taking an excessively large dose. The International Olympic Committee has established a
maximum acceptable urinary caffeine level o f 12 jj-g/ml. Generally, a 9 mg/kg dose will
not exceed this limit (Graham & Spriet, 1991; Van Soeren, Sathasivam, Spriet, &
Graham, 1993). A lethal dose of caffeine ranges between 40 and 50 mg/kg but may be
lower if other drugs are being taken concurrently. It appears that a dose between 3-6
mg/kg provides the optimal balance between performance enhancement and side effects
which include jitters, gastrointestinal discomfort, and an inhibition in the ability to
perform meticulous movements (Spriet, 1995).
While part o f the effectiveness o f caffeine as an ergogenic aide is based on
caffeine dose size, a second factor is the relative amount o f caffeine consumed daily. The
question to be considered is whether minimal dietary caffeine supplementation is
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ergogenically more effective than habitual caffeine use. Most studies agree that habitual
caffeine use tends to impair the catecholamine response (Van Soeren et al., 1993;
Robertson, Wade, Worionan, Woosley, & Oates, 1981). Van Soeren et al. (1993) studied
the effects o f caffeine in naive and habitual caffeine users. Their results indicated that
caffeine naive users showed a significant increase in epinephrine levels after consuming a
5 mg/kg caffeine dose and exercising on a cycle ergometer, while caffeine habituated
participants showed no such increase in epinephrine levels. Robertson et al. (1981)
controlled the diet of eighteen participants for fourteen days. Participants were randomly
assigned to one o f two groups. Group I received a placebo beverage with each meal
while Group H received a placebo beverage with each meal during days one through three
and ten through fourteen with caffeine beverages being consumed during days four
through ten. Group II plasma epinephrine and norepinephrine levels were significantly
elevated on day four but returned to baseline levels within four days, while the plasma
catecholamine levels did not significantly change in the control group.
With respect to short term high intensity exercise, there are three main effector
sites for caffeine in the human body, the central nervous system, the neuromuscular
junction, and the muscle contractile process (Williams, 1991). Each has been implicated
in the observed benefits o f caffeine. Caffeine has pronounced effects on the central
nervous system including reduced sleep, reduced reaction time, enhanced mental
sharpness and neuromuscular transmission. The mechanism by which caffeine produces
these results is unclear. Two hypotheses have been offered to explain the central nervous
system effects. These are cyclic AMP accumulation through phosphodiesterase
inhibition and competitive adenosine receptor blockade.
Indirectly, caffeine has been shown to promote cAMP accumulation (Sutherland

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

7
& Rail, 1958).

Cyclic AMP mediates the actions o f many neurotransmitters and

hormones in the central nervous system (Sutherland, Robison, & Butcher, 1968), while
the enzyme phosphodiesterase mediates cAMP breakdown (Choi, Shamim, Padgett, &
Daly, 1988). Blocking phosphodiesterase will result in cAMP accumulation, prolonging
cAMP function, thus promoting the actions o f neurotransmitters and hormones in the
central nervous system. However, the plasma caffeine levels required to initiate this
response are estimated to be 300;/g/ml which is well in excess o f acceptable doses for
humans (Fredholm 1985).
The second hypothesis proposed to explain the effects o f caffeine on the central
nervous system is a competitive adenosine receptor blockade. Adenosine is a nucleotide
which inhibits neurotransmitter release. Caffeine appears to compete with adenosine for
xanthine-sensitive adenosine receptors (Williams, 1987). There are two different
adenosine receptor types, a high affinity receptor, A l, and a low affinity receptor, A2
(van Calker, Muller, & Hamprecht, 1979). The high affinity receptor has been shown to
suppress physiological functions while the low affinity receptor has the opposite effect
(Dunwiddie, 1985). As caffeine blocks both A l and A2 adenosine receptors,
neurotransmitter turnover is improved. The dosage required to achieve measurable
changes in receptor binding is well within the limits o f human consumption. Rail (1980)
found that competitive adenosine receptor binding was possible with plasma caffeine
concentrations ranging fi’om 5 to 30/zM. Furthermore, caffeine's virtual lack o f barriers
makes it accessible to the unique xanthine-sensitive adenosine receptors located
throughout the body. While adenosine receptor blockade accounts for the majority o f
caffeine's major effects, other mechanisms are suspected of playing important, but less
remarkable, roles such as stimulation, calcium release and diminished calcium reuptake
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by the sarcoplasmic reticulum. (Amaud 1987).

Side Effects
While caffeine’s primary physiological mode o f action has not been established,
several o f side effects have been noted. These range from sleepless nights and heightened
anxiety to quicker reflexes, heightened mental sharpness, and improved neuromuscular

transmission.

Reduced Sleep
Caffeine, through central nervous system stimulation, has a dramatic effect on
sleep and sleep depravation. It has been suggested that caffeine’s largest central nervous
system effect in adults is on sleep (Dews, 1982). Numerous studies have found that
caffeine produces a delay in sleep onset, a reduction in sleep time, increased body
movements during sleep and an increase in the number o f spontaneous awakenings
(Muller-Limmroth cited in Battig, 1985; MuUin, 1933; Brezinova, 1975). People most
susceptible to sleep disruption tend to be caffeine non-users or caffeine naive individuals.
One study did not find an extended time to sleep onset (Nicholson & Stone, 1980).
However, this was attributed to the dose being administered immediately prior to sleep
which did not allow for adequate caffeine absorption to achieve peak plasma levels.

Reaction Time
Another aspect o f central nervous system stimulation which has been extensively
studied is reaction time. Faster reaction times have been reported (Rapoport, Jensvold,
Elkins, Buchsbaum, Wiengartner, Ludlow, Zahn, Berg, & Neims, 1981; Jacobson &
Edgley, 1987; Roache & Griffiths, 1987) with caffeine ingestion. Overall the results are
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often contradictory and generally lacking in consistency. Much o f the variability in
results may be due to differences in the caffeine doses administered. Horst and Jenkins
(1935) found that a 3 mg/kg dose resulted in consistently reduced reaction times while a 2
mg/kg dose resulted in inconsistent reductions in reaction time. Additionally, large doses
o f caffeine may provide no benefits at all. Jacobson and Edgley (1987) performed a
study in which 300 mg caffeine, 600 mg caffeine or placebo were administered.
Participants were situated in a chair with a bright light positioned directly in fi’ont o f the
chair. Additionally, participants placed the palm o f their hand on a breaker switch
located 60 degrees fix>m horizontal on their right side. The reaction time test was initiated
when the bright light was turned on and concluded when participants removed their hand
off the breaker switch. A significant improvement in reaction time was found with the
300 mg dose while no improvements were found in the placebo or the 600 mg dose.
Roache and Griffiths (1987) also tested reaction time with 200,400, and 600 mg doses o f
caffeine. A computerized reaction time task required the participants to distinguish
between randomly selected even and odd numbers ranging fi’om 1 to 8. In response to the
odd or even number, participants pressed a left or right telegraphing key, respectively.
Trials began with the presentation o f a randomly selected digit and terminated when
either key was depressed. The time interval between trials varied fi-om 0.5 seconds to 5
seconds apart. Test results indicated a significant reduction in reaction time with the 400
mg dose but no significant change in reaction time with the 200 or 600 mg dose. These
results suggest that an optimal dose o f caffeine for improving reaction time is between
300 and 400 mg depending on the body mass o f the individual.
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Mental Sharpness
Mental sharpness is defined as the ability to maintain focus on a task over a
prolonged length o f time. Caffeine has a distinct effect on this fimction of the central
nervous system. It is believed that caffeine benefits mental sharpness by delaying the
onset o f metal fatigue, evidenced by a study performed by Fagen, Swift, and Tiplady
(1988) in which participants were administered a 200 mg dose prior to performing
prescribed tasks for one hour. The largest improvements in performance were found in
the second half o f the one hour test. However, the theory o f delayed onset o f mental
fatigue has been contested by Battig and Buzzi (1986) who presented the task stimulus at
a varied rate which participants could control, rather than at a fixed rate. For each correct
response the interval between stimuli was decreased, and for each incorrect response the
interval between stimuli was increased. The purpose o f this study was to determine
whether delayed onset of fatigue was truly responsible for improved mental sharpness.
By adjusting the interval between task stimuli, processing rate rather than error rate,
could be measured with respect to performance. Processing rate increased with increased
caffeine doses o f 150 and 450 mg over each ten minute segment of the testing session.
These
results provide evidence that improvements in mental performance are due to more than a
delay in mental fatigue.

Neuromuscular Transmission
Caffeine has been shown to enhance neuromuscular transmission (Brekenridge,
Bum, & Matshinsky, 1967; Hofinaim, 1969; Wilson, 1973). Eke-Okoro (1982) studied
reflex action in the lower leg in the presence o f several variables including caffeine. The
procedure was to electrically induce dorsiflexion and the subsequent plantar reflex was
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measured in participants who had consumed an average o f 125 milligrams o f caffeine.
Results o f this study showed that the stimulus threshold was reduced and the muscle
afferent and efferent amplitudes were enlarged one hour after caffeine ingestion.
Brekenridge et al. (1967) proposed that increased muscular cyclic AMP is responsible for
the enhanced rate o f neuromuscular transmission. However, this theory was discounted
when it was learned that caffeine’s effects are directed toward the presynaptic neuron
(Goldberg & Singer, 1969; Hofinann, 1969). In particular, elevated levels of
neurotransmitter release were found. Apparently, caffeine increases the quantity of
neurotransmitter released per stimulus, while the speed o f the transmission is not affected
by caffeine.

Free Fatty Acid Release
Recently, Graham and Spriet (1991) have shown that caffeine significantly
increases catecholamine levels in the blood. Specifically, their results showed a rise in
plasma epinephrine levels after consuming 6 mg/kg or more o f caffeine. The effects o f
increased levels of epinephrine include increased free fatty acid release, increased heart
rate, vasoconstriction, suppressed visceral muscle activity, and bronchiole dilation
(Marieb, 1992). Each o f these may be beneficial during exercise. However, the most
notable o f these effects is enhanced firee fatty acid release because o f a purported
glycogen sparing effect (Chesley, Hultman, & Spriet, 1994; Graham & Spriet, 1991).
Increased plasma free fatty acid levels promote an accumulation of cAMP
activating lipoprotein lipase and breaking down triglycerides into glycerol and free fatty
acids. The advantage of an elevated free fatty acid level is a metabolic shift toward
increased lipid oxidation which, in turn, reduces the demand for glucose and glycogen.
Glycogen sparing in this manner, would allow the athlete to exercise at a higher
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percentage o f maximal capacity for a longer period o f time. Glycogen sparing through
lipid oxidation has been shown to occur during the first 15 to 20 minutes o f exercise at
80% o f maximal aerobic capacity (VO^max) (Spriet, MacLean, Dyck, Hultman,
Cederblad, & Graham, 1992). Spriet et al. (1992) performed a study with the dual
purpose o f examining the chronology o f glycogen use during exercise in addition to
identifying possible mechanisms for this glycogen sparing. Participants cycled to
exhaustion at 80% VO^max one hour after ingesting 9mg/kg caffeine. Muscle biopsies
were taken prior to the beginning o f exercise, at the 15 minute mark, and at the
completion o f exercise. Results indicated a significant increase in the time to exhaustion
between caffeine (96.2 ± 8.8 min) and placebo (75.8 ± 4.8 min). Furthermore, glycogen
use was significantly reduced in the first 15 minutes of exercise during the caffeine vs.
placebo trial (4.7 ±1.5 vs. 10.6 ±1.3 mmol-kg dry muscle '-minute '). The prolonged time
to exhaustion during the caffeine exercise bout conformed with the length o f time in
which glycogen sparing occurred.
Several studies have shown a glycogen sparing effect of increasing fi-ee fatty acids
(Essig, Costill, & VanHandel, 1980; Erickson, Schwarzkopf, & McKenzie, 1987; Spriet
et al., 1992; Graham, Rush, & van Soeren, 1994), while others have not (Tamopolsky,
Atkinson, MacDougall, Sale, & Sutton, 1989; Toner, Kiikendall, Delio, Chase, Cleary, &
Fox, 1982; Ravussin, Bogardus, Scheidegger, LaGrange, Horton, & Horton, 1986).
Typically, the respiratory exchange ratio (RER) has been used to estimate the changes
seen in ftiel metabolism with caffeine consumption. However, two separate studies
analyzed caffeine induced metabolic shifts directly via post-exercise muscle biopsy
(Essig et al., 1980; Erickson et al., 1987). During 30 minutes of exercise at 69%VO,max
, Essig et al. (1980) found a 42% reduction in muscle glycogen use following ingestion o f
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5 mg/kg caffeine. Similarly, Erickson et al. (1987) found a 30% reduction in muscle
glycogen use after 90 minutes o f exercise at 65 to 70%VO2max with a caffeine dose of 5
mg/kg body weight. The results o f these studies suggest that increased uptake o f free
fatty acids in the muscle may suppress the need for glycolysis or glycogenolysis.
Increased lipid oxidation results in an increase in citrate concentration. Citrate inhibits
phosphofructokinase (PFK) which limits the conversion o f fructose-6-phosphate to
fructose 1,6-bisphosphate, a rate limiting step in glycolysis. The result is a glycogen
sparing effect through accumulation o f glucose-6-phosphate.
The validity of glycogen sparing induced by elevated plasma epinephrine and the
resultant increase in free fatty acid levels has been questioned in recent years. Two
studies performed by Van Soeren (1993, 1996) have indicated that elevated epinephrine
levels have no significant impact on RER or free fatty acid levels. In the first study, Van
Soeren et al. (1993) examined the metabolic and catecholamine responses to caffeine in
both caffeine users and non-users. Non-users performed two exercise bouts after
consuming either 5mg/kg caffeine or placebo. Exercise bouts were completed on a cycle
ergometer at 50% o f maximal oxygen consumption and lasted for one hour. Caffeine
users performed three exercise bouts designed to control for caffeine use. The first test,
under placebo conditions, occurred after four days o f voluntary caffeine abstinence. Over
the next fourteen days, participants were given a 5mg/kg caffeine dose in two parts or a
placebo. The second and third exercise tests occurred at seven day intervals and were
similar to the exercise tests of the caffeine non-users. The results indicated that, despite
significantly elevated epinephrine levels, non-users failed to show a decrease in RER or
increase in free fatty acid concentration. Caffeine users were found to have elevated
epinephrine levels during exercise under placebo conditions. However, caffeine users
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also failed to show a change in free fatty acid concentration or RER. Because
epinephrine stimulates glycogenolysis, it is possible that any benefits gained fix>m
glycogen sparing via elevated plasma fiue fatty acid levels would be neutralized. In the
second study. Van Soeren, Mohr, Kjaer, and Graham (1996) tested six tetraplegics and
two paraplegics to determine whether caffeine directly stimulated tissues or acted
indirectly via increased epinephrine levels induced by caffeine. Subjects were given
either a placebo or 6 mg/kg o f caffeine. Epinephrine levels in the tétraplégie were not
significantly elevated during the caffeine trial while plasma free fatty acid levels were
elevated. Conversely, paraplegics showed a significant increase in epinephrine, similar to
what would be expected from resting able-bodied individuals, and an increase in plasma
free fatty acids. These results indicate that increased free fatty acid levels are not
dependent on elevated epinephrine levels, and instead suggest that caffeine directly
effects adipose tissues.
The concept that caffeine results in glycogen sparing has two potential limitations.
First, glycogen sparing has only been shown to benefit endurance athletics engaging in
aerobic exercise. High intensity exercise requires energy production which may exceed
the oxidative capacity preventing the maximization o f the potential advantages presented
by elevated plasma free fatty acid levels. In fact, there may not even be a glycogen
sparing effect in high intensity exercise. Jackman, Wendling, Friars, and Graham, (1996)
studied the effects of caffeine on high intensity exercise. Fourteen participants ingested
a 6mg/kg caffeine dose and cycled at 100% o f maximal oxygen capacity three times,
separated by six minutes o f rest. The first two exercise bouts were two minutes in
duration at a controlled power output. The third exercise bout continued to exhaustion.
Jackman found that time to exhaustion was improved with caffeine compared with
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placebo. Additionally, lactate production was higher during the caffeine trial. They
concluded that the ergogenic benefit o f caffeine was not the result of glycogen sparing.
A second limitation of glycogen sparing by caffeine is related to dietary
constraints imposed on the subject. It has been reported that diets high in carbohydrate
negate any caffeine-induced, glycogen sparing effects (Weir, Noakes, Myburgh, &
Adams, 1987; Giles & McLaren, 1984). Weir et al. (1987) tested six trained runners
under conditions o f a high fat content meal alone, a high carbohydrate meal followed by
caffeine ingestion, or a three day diet consisting o f high fat or high carbohydrate meals in
combination with caffeine. Following a dose o f 6.5 mg/kg caffeine, participants
exercised for 120 minutes at 75% o f maximum oxygen uptake. The result was that free
fatty acid levels did not rise as anticipated after a high carbohydrate diet and high
carbohydrate meal followed by caffeine ingestion. Similarly, Giles and McLaren (1984)
exercised participants for 120 minutes on a treadmill at 75% maximum oxygen uptake
one hour after ingesting a 5 mg/kg caffeine dose alone or in combination with glucose
ingestion. They found a significant decrease in peak plasma free fatty acid levels with
glucose and caffeine ingestion compared to caffeine alone. These results have
implications for athletes who carbohydrate-load prior to competitive events such as a
marathon or triathlon. However, other studies contradict these results and show that
caffeine-induced performances are not affected by high carbohydrate diets (Spriet et al.,
1992). Spriet cycled eight subjects to exhaustion at 80% maximal oxygen uptake one
hour after ingesting a 9 mg/kg caffeine dose or placebo. Each participant was instructed
to consider the exercise as a hard workout in their weekly training program and to
maintain diets similar to precompetition diets. Analysis of each subject’s diet showed an
average of 59.6% carbohydrate content prior to testing. Despite consuming a high
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carbohydrate diet, participants cycled significantly longer in the caffeine trial than the
placebo trial.
Although it is largely understood that elevated catecholamine levels promote
elevated fi’ee fatty acid levels, the cause and effect relationship o f caffeine and elevated
catecholamine levels is less clear. The effects o f caffeine on catecholamine secretion are
confounded by studies ( Graham & Spriet, 1991; Spriet et al., 1992) that failed to show an
increase in norepinephrine despite an increase in epinephrine, suggesting that the effects
o f caffeine on catecholamine secretion are not affecting the sympathetic nervous system.
Rather, caffeine appears to be acting on the adrenal medulla. A greater epinephrine
response to caffeine has also been found during exercise (Kjaer, Bangsbo, Lortie, &
Galbo, 1988), which was attributed to an increased rate o f secretion rather than a
decreased rate o f epinephrine reabsorption.
While glycogen sparing may be the most significant ergogenic effect o f caffeine,
other ergogenic benefits have been reported. Several studies report that VO,max is
enhanced by caffeine consumption (Toner et al., 1982; Wiles, Bird, Hopkins, & Riley,
1992). Toner et al. (1982) found a statistically significant increase in VO,max in
subjects pedaling a cycle ergometer following caffeine ingestion relative to a control
group. Wiles et al. found performance improvements in 1500 meter run and “finishing
burst” sprint times following the consumption o f caffeinated coffee. Additionally, eight
o f the ten participants in this study recorded higher VO, values during the caffeine trial.
Wiles et al. (1992) observed that the higher VO, levels were probably due to faster
running speeds during the caffeine trial. However, the faster running speeds could also
be attributed to a general decrease in the perception o f fatigue, which could cause
participants to select a higher speed. Conversely, research exists which fails to show an
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increase in VO^max with caffeine treatment (Powers, Byrd, Tuliey, & Callender, 1983;
Dodd, Brooks, Powers, and TuU ^, 1991). Powers et al. (1983) studied, seven
participants who performed a graded exercise test on a cycle ergometer one hour after
consuming 5 mg/kg o f caffeine or placebo. Initial resistance was 30 Watts and was
increased by 30 Watts every three minutes. No difference in maximal oxygen uptake or
time to exhaustion was found between caffeine and placebo trials. Dodd et al. (1991)
used a similar test protocol in which initial resistance began at 50 Watts and increased by
30 Watts every two minutes. Nine caffeine habituated participants were compared with
eight participants who abstained from caffeine consumption or were considered caffeine
naive. Participants were given a placebo, 3 mg/kg, or 5 mg/kg caffeine one hour prior to
beginning the test. While VO^max was significantly increased in caffeine naive
participants, this only occurred after consuming 5 mg/kg caffeine. There was no
significant difference in VO^max among caffeine habituated participants.

Caffeine and Skeletal Muscle
Skeletal muscle appears to be the target organ for many o f caffeine’s purported
ergogenic effects. Because caffeine almost completely equilibrates with total body water,
the highest concentration o f caffeine can probably be found in skeletal muscle (Burg,
1975). It has been shown that type 1 and H skeletal muscle fibers have different levels o f
sensitivity to caffeine. Deuster, Bockman, & Muldoon, (1985) studied muscle
contractures induced by caffeine. Isolated strips o f cat soleus muscle (100% type I fibers)
and gracilis muscle (95% type H fibers) were incubated with doses of caffeine ranging
from 0.25 to 16 mM. The results showed that type I muscle fibers were significantly
more sensitive to caffeine than type H muscle fibers. This difference in sensitivity to
caffeine between type I and type H muscle fibers was also found in human skeletal
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muscle by Mitsumoto, Deboer, Bunge, Andrish, Tetzlaff, and Cruse, (1990). Caffeine
has been shown to stimulate calcium release from its storage site in the sarcoplasmic
reticulum (Rail, 1985). This stored calcium can be subdivided into calcium-sensitive and
inositol triphosphate-sensitive reservoirs. The action o f caffeine on calcium stores in the
sarcoplasmic reticulum may be inconsequential, however, because the dose of caffeine
required to elicit a significant mobilization o f calcium is toxic in vivo (Fredholm 1985).
While a caffeine dose o f 9 mg/kg body weight will produce an approximate plasma
caffeine concentration o f 15 /zg/ml, it was determined that plasma caffeine concentrations
of approximately 300 /Ug/ml would have to be achieved to see any significant results on
sarcoplasmic reticulum calcium release. Alternately, Poledna and Morad (1983)
suggested that caffeine, rather than stimulating calcium release, suppressed calcium
reuptake into the sarcoplasmic reticulum which would also facilitate muscle contraction.
However, the caffeine dose required to achieve this effect is again prohibitive in vivo.
In vitro studies performed on muscle tissue of individuals susceptible to malignant
hyperthermia showed intensified muscle contractions after subjects consumed a caffeine
load compared with muscle tissue from normal people (Britt, 1979; Britt, Endrenyi, Scott,
& Frodis, 1980; Gronert, 1980). It was presumed that the intensified muscle contractions
were due to an increased plasma calcium level in the malignant hyperthermia muscle.
The effects o f caffeine on muscle tension and maximal voluntary force have also
been studied to determine any beneficial effects from caffeine. Williams (1987) tested
hand grip strength under caffeine and placebo conditions and found no difference in force
production between the two conditions. Conversely, it has been shown that caffeine
increases maximal tension production o f the adductor poUicis when electrically
stimulated (Lopes, Aubier, Jardin, Aranda, & Macklem, 1983). While improvements
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were found at submaximal frequencies o f stimulation (sSO Hz), no improvements
occurred at stimulation frequencies above 50 Hz. Additionally, maximal voluntary
contraction have shown no improvement Conversely, several studies have failed to show
a significant effect of caffeine on tension or the maximal voluntary level o f force
produced during a muscle contraction (Bugyi, 1980; Lopes et al., 1983; Taraopolsky et
al., 1989; Williams, 1987). It was theorized that increased motor unit recruitment might
occur during submaximal contractions as evidenced by an increase in tension produced at
submaximal electrical stimulation (Lopes et al., 1983). However, Williams (1987)
measured handgrip strength after caffeine ingestion and found no increase in motor unit
activation as determined by an electromyogram. Additionally, caffeine did not improve
the motor unit recruitment to force production ratio with submaximal handgrip
contractions.

Caffeine and Performance
The effects of caffeine supplementation on performance have been investigated in
several competitive situations, primarily endurance events. In general caffeine appears to
have a positive ergogenic effect on endurance exercise. Costill, Dalsky, and Fink (1978)
examined the exercise performance o f nine competitive cyclists pedaling at 80% of
VO^max. Participants ingested either 330 mg o f caffeinated coffee or decaffeinated
coffee one hour prior to the onset o f exercise. Average time to exhaustion improved from
75.5 minutes under placebo conditions to 90.2 minutes under caffeine conditions. Spriet
et al. (1992) administered a 9 mg/kg caffeine dose to participants, one hour prior to
cycling at 80% o f VO^max, and found a significant improvement in time to exhaustion
during caffeine trials (96.2 ± 8.8 min) rather than placebo trials (75.8 ± 4.8 nun).
The effects o f caffeine on short term exercise are not as clear. Collomp, Caillaud,
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Audran, Chanal, and Prefaut (1990) studied participants who cycled at 100% o f their
VOjmax until the required level o f woric could no longer be maintained. While
participants work times were increased in the caffeine trial, the results were not
significantly different fium the placebo trial. Wiles, et al. (1992), on the other hand,
showed a statistically significant improvement in performance with caffeine. Participants
ran a 1500 meter time trial on a treadmill. Each participant also had to complete the run
with a one minute finishing burst under either caffeine or placebo conditions. In the
caffeine trials, there was a decrease in the amount o f time needed to complete the 1500
meter run, and a faster one minute finishing burst, both o f which were significantly
different fi’om the control trial.
It is possible that the ergogenic effects o f caffeine may be related to the athletic
level o f the participants. The ergogenic effect appears to be more prevalent when
competitive or highly trained athletes are used as participants. For example, Collomp,
Ahmaidi, Chatard, Audran, and Prefaut (1992) studied freestyle sprint performance in
two distinct groups. The first group consisted o f seven swimmers who had been training
an average o f five times per week for at least four months, and had recently undergone
sprint training in anticipation o f a forthcoming swim meet. The second group consisted
o f seven subjects who were former competitive swimmers, but who had not practiced
consistently, though they were occasionally swimming. All o f the subjects were asked to
abstain from any caffeinated drinks for one week prior to the test. Subjects were
randomly given a gelatin capsule containing either 250 mg o f caffeine or a placebo, and
swam two 100-m sprints, separated by a twenty minute rest period. The time required to
complete the 100-m sprint was significantly decreased in the trained subjects but not in
the untrained subjects with caffeine. Collump also noted that while blood lactate
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concentrations were significantly increased in both the trained and untrained swimmers,
the trained swimmers had a higher relative blood lactate content after each 100-m sprint
regardless o f whether caffeine or placebo was being used, possibly due to a decline in the
perception o f fatigue with caffeine in trained athletes.
In summary, caffeine has been reported to have three main effector sites, the
central nervous system, the neuromuscular junction, and the muscles contractile
machinery. Two hypotheses proposed to explain central nervous system stimulation
include phosphodiesterase inhibition and competitive adenosine receptor blockade
through caffeine consumption. Through caffeine’s effects on various physiological
processes, a multitude o f ergogenic benefits have been proposed, ranging fi-om a
glycogen sparing effect to sharper mental acuity and quicker reaction time. Most o f the
research has focused on endurance events which are aerobic by nature with very little
research targeting high-intensity intermittent exercise. Therefore, the purpose o f my
study is to examine the effects of caffeine on high-intensity intermittent cycle ergometery
to exhaustion.
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CHAPTERS

METHODOLOGY

Subjects
Seven apparently healthy male participants volunteered for this study.
Participants were selected based on their diet which consisted of minimal to negligible
amounts o f daily dietary caffeine. Daily caffeine intake was estimated to be less than 75
mg per day. The mean physical attributes (and standard deviation) of the participants
were: age in years = 26.00 (±1.83), body mass = 76.92 kg (±10.56), and peak V02 =
46.99 ml/kg/min. (±7.37).

Pretest
One week prior to the onset o f the study, participants performed a peak oxygen
uptake test on a (Quinton cycle ergometer. Participants were connected to a Vista
metabolic measurement system (Vacumed Inc., Ventura, CA) via a one way non
rebreathing mask. Participants were also fitted with a Vantage heart rate monitor. After a
5 minute warmup, participants began pedaling at 60 to 80 revolutions per minute, with
initial resistance set at 50 Watts. Resistance was increased by 25 Watts every minute
until peak oxygen consumption levels were determined. At the conclusion o f the peak
oxygen uptake test, a five minute warm down period followed. Following the pretest.
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participants were instructed to abstain from caffeinated products for the next two weeks.
Test Protocol
Upon arrival on a test day, participants’ body mass was determined, and a 50//1
blood sample was drawn with two heparinized microtubules. Participants consumed a
300 ml cup o f decaffeinated coffee containing either caffeine (6 mg/kg body weight) or
placebo. After consuming the beverage, participants waited for one hour to allow for
caffeine absorption. During this time, an explanation o f the exercise protocol was given
to participants with an opportunity to receive answers to any questions. Toward the end
o f the absorption period, participants were seated on the cycle ergometer and outfitted
with a Vantage heart rate monitor. Immediately prior to the beginning of the exercise
protocol, a second 50^1 blood sample was drawn from each participant. The test protocol
began with a five minute warmup at 50 Watts resistance followed by the test protocol
sequence. Each sequence consisted o f cycling for 60 seconds at 120% of the maximal
power output achieved during the peak VO, pretest, with recovery periods o f cycling at
50 Watts for 120 seconds. The sequence was computer programmed to generate accurate
force load and interval duration. The exercise protocol was terminated when participants
were unable to maintain a minimum o f 60 revolutions per minute for 10 consecutive
seconds, hnmediately following the conclusion o f the test, a third 50//1 microtubule
blood sample was drawn. A five minute warm down followed the end of the exercise
test.
The participants were instructed to abstain from caffeine and report one week later
for their second trial. Participants followed the same procedure as in the first trial, except
participants received the opposite treatment to the first. The placebo and caffeine trials
were administered to participants in a counterbalanced design. Following the second
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trial, participants were asked whether they could distinguish between the two 300
milliliter beverages which they consumed, and which test protocol was more difficult.
Blood lactate levels were determined using a Yellow Springs Model 23L lactate
analyzer (Yellow Springs Instruments, Yellow Springs, OH). Plasma caffeine levels
were determined using a Gilford 260 spectrophotometer at a wavelength o f 273
nanometers according to a modification o f the procedure of Axelrod and Reichenthal
(1953), and Routh, Shane, Arredondo, and Paul (1969) (see Appendix HI). Further
revisions were necessary to accommodate smaller blood samples than those required in
the original procedure.
A double blind crossover design was implemented in this study to help control
internal validity. Since this was a within subjects study, the statistical analysis used was
a one way ANOVA with repeated measures for caffiene dose and paired t-Test for time to
exhaustion, work stages completed, total power output, and lactate concentration.
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CHAPTER 4

RESULTS

Plasma Caffeine Concentration
In the caffeine trial, plasma caffeine levels were significantly elevated over
baseline levels one hour after consuming caffeine (p<0.001) (Figure I). Baseline caffeine
levels were 1.66 ± 0.2lAig/ml while post absorptive caffeine levels were 6.72 ±
1.40^g/ml. Baseline and one hour post-absorption caffeine levels during the placebo trial
were 1.51 ± 0.22/^g/ml and 1.95 ± 0.30^g/ml respectively, and failed to reach
significance (Figure 2).

Time to Exhaustion
Ingestion of 6 milligrams o f caffeine per kilogram body weight one hour prior to
intermittent cycling at 120% of peak power did not significantly increase exercise time
over the placebo condition. The mean time to exhaustion during the caffeine trial was
12.54 ± 5.86 minutes while the placebo condition yielded a mean time to exhaustion o f
12.31 ± 6.62 minutes (Figure 3). The difference in performance by woric stages failed to
reach significance. The mean number o f work stages completed was 4.68 ± 1.94 and 4.59
± 2.24 for caffeine and placebo trials respectively (Figure 4). The difference in total
power output between caffeine and placebo trials was not significantly different (Figure
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5). The mean total power output for caffeine and placebo trials was 1661.61 ± 701.75
Watts and 1630.38 ± 801.33 Watts respectively.

Blood Lactate Concentration
Figure 6 indicates blood lactate concentration achieved during caffeine and
placebo trials. Blood lactate concentration averaged 11.33 ± 1.04 mM and 11.63 ± 1.89
mM during caffeine and placebo trials respectively and failed to reach significance.
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CHAPTERS

DISCUSSION
This study examined the effects o f caffeine on healthy, active, college age males
performing high-intensity, intermittent cycling. The primary finding of this study was
that caffeine failed to significantly increase time to exhaustion over a placebo. Caffeine
levels were significantly elevated during the caffeine trial compared with baseline levels.
Additionally, plasma lactate levels were not significantly different between caffeine and
placebo.
These findings differ firom those of Trice and Haymes (1995). They investigated
the effects o f caffeine on high-intensity, intermittent exercise to exhaustion and found a
significant increase in performance time o f 16.25 minutes during the caffeine trial in
addition to a 20 minute increase in the range o f time to exhaustion. The exercise protocol
used by Trice and Haymes and the protocol adopted for this study were based on two
previous studies performed by Astrand, Astrand, Christensen, and Hedman (1960,1960).
Astrand et al. studied the effects o f altering the length o f work/rest periods while
maintaining the work/rest ratio at I to 2 or I to 4. The total quantity of work to be
performed within a 30 minute period was standardized to allow for direct comparisons
between tests. Plasma lactic acid concentration was measured, while the same amount o f
work over a 30 minute period was maintained. Results indicated that a 60 second bout of
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high-intensity exercise followed by a 120 second recovery period yielded lactic acid
values o f 142 mg per 100 ml, which was significantly higher than 60 seconds o f work
followed by 120 seconds o f recovery which resulted in peak lactic acid values o f 114 mg
per 100 ml. Based on these results, it was decided to adopt the 60 second work and 120
second recovery workrrest ration for the current study. It was also decided that
participants would cycle at 120% o f their maximal power output.
Trice and Haymes exercise protocol, which consisted o f three 30 minute
repetitions o f 60 second work and rest intervals at 85 to 90% of maximal power output
resulted in plasma lactate levels o f 4.00 ± 0.70 and 4.24 ± 0.86 for caffeine and placebo
trials respectively. The exercise protocol for the current study attained plasma lactate
levels o f 11.33 ± 1.04 and 11.63 ± 1.89 for caffeine and placebo trials respectively. It is
possible that Trice and Haymes found a significant improvement in time to exhaustion
because participants reached a balance point between lactate production and removal.
Additionally, if participants were cycling at 85% of V02max, recovery during the early
stages o f exercise might permit glycogen sparing through increased lipolysis. Previous
studies have suggested that caffeine may inhibit lactate production via increased lipid
oxidation resulting in a decrease in utilization o f glucose and glycogen (Chesley, 1994;
Graham & Spriet, 1991). Such benefits have been reported to occur within the first 15 to
20 minutes o f exercise at 80% o f maximal aerobic capacity (Spriet et al. 1992). This
spared glycogen is then available for use in the later stages o f exercise, extending the time
to exhaustion. Trice and Haymes reported an increase in the time to exhaustion o f 16.25
minutes. In the current study, an equilibrium between lactate production and elimination
was unlikely because o f the higher intensity o f work load was prohibitive. At 120% of
maximal aerobic capacity, participants were exercising well above the lactate threshold
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making glycogen sparing unlikely.
It has been speculated that caffeine may be beneficial during anaerobic exercise.
Collomp et al. (1992) compared a group o f highly trained swimmers with occasional
swimmers who were formerly highly trained. Each group performed two 100 meter
fi-eestyle sprints separated by 20 minutes, under both caffeine and placebo conditions.
Blood lactate levels were similar for both groups regardless o f the caffeine or placebo
condition. However, only the highly trained swimmers improved their sprint speed
during both sprints. Collomp et al. speculated that specificity o f training may be
necessary to obtain any ergogenic benefits from caffeine during supramaximal exercise.
While participants for the current study were active, none had specifically trained on a
cycle ergometer for any length o f time under anaerobic conditions.
It is possible that the level o f physical training may also be important in deriving
ergogenic benefits from caffeine during short term, high intensity exercise. Highly
trained athletes appear to draw greater benefits from caffeine than less well conditioned
athletes (Collomp, Ahmaidi, Audran, Chanal, & Prefaut, 1991; Collomp et al., 1992;
Wiles et al., 1992). Type I muscle fibers, which are highly oxidative, have been shown
to be more sensitive to caffeine than type II fibers (Duester, 1985; Mitsumoto, et al.,
1990). One o f the adq)tations to aerobic exercise is an increase in oxidative capacity of
muscle as evidenced by an increase in both size and number o f mitochondria (Essig and
White, 1981). While the participants for this study were active, they were not considered
highly trained. Whether caffeine would provide an advantage to highly trained endurance
athletes during intermittent high-intensity exercise remains to be determined.
A recent study suggested that the manner in which caffeine is administered might
have an impact on the ergogenic benefits associated with caffeine. Graham, Hibbert, and
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Sathasivam (1995) reported that caffeine administered in tablet form may be more
effective than regular coffee or caffeine dissolved in decaffeinated coffee. Participants
performed 5 exercise tests in which they ran to exhaustion at 85% o f their V02max one
hour after consuming either a caffeine or placebo capsule with water, or regular coffee,
decaffeinated coffee or decaffeinated coffee with a caffeine supplement. The caffeine
dose and volume o f liquid to be consumed were both standardized to eliminate any
variability between tests. Graham et al. found no difference in time to exhaustion
between the three beverages and placebo capsule. However, participants ran significantly
longer after consuming caffeine in capsule form. Plasma epinephrine levels measured
throughout the test indicated a significant increase between caffeine and placebo
treatments, but no significant difference between caffeine treatments. It was postulated
that caffeinated and decaffeinated coffee contain an additional element which negates the
ergogenic benefits associated with caffeine.
In this study, caffeine was dissolved in a 300 mg cup of decaffeinated coffee.
Following the conclusion o f the last exercise test, six o f seven participants correctly
identified which exercise test contained caffeinated beverages. Five o f the participants
felt jittery prior to beginning the caffeine trial exercise protocol and one participant
experienced post-exercise gastric discomfort associated with the caffeine beverage.
Despite experiencing characteristics associated with consuming large quantities o f
caffeine, participants were unable to significantly improve time to exhaustion during the
caffeine trial. This lends some validity to the belief that caffeine dissolved in
decaffeinated coffee will increase levels of plasma epinephrine without providing any
ergogenic benefits.
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CHAPTER 6

CONCLUSIONS
Caffeine has been extensively studied in recent years in an attempt to capitalize on
it’s potential ergogenic benefits. However, results are often inconsistent and
contradictory, making an accurate assessment o f caffeine’s potential as an ergogenic aid a
difficult task. This study focused on the effects o f caffeine during high-intensity,
intermittent exercise to exhaustion. The results o f this study indicated that caffeine naive
participants who consumed a large dose o f caffeine one hour prior to undertaking a highintensity, intermittent bout o f exercise did not significantly improve the length o f time to
exhaustion. Though a caffeine dose o f this magnitude will significantly elevate plasma
caffeine levels, the level o f exercise intensity appears to be too high to take advantage of
the ergogenic benefits associated with caffeine during exercise of moderate intensity.
Ergogenic benefits may be attainable at this level o f work if the participants are highly
trained and target their training toward anaerobic cycling sprints. Results o f future
caffeine studies in this realm are anticipated to be variable depending on individual
differences in age, daily caffeine ingestion, and fitness level.
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APPENDIX I

STATISTICAL RESULTS
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Table 1: Plasma Caffeine Level - Caffeine Trial
Anova: Single Factor
Pre/Post Plasma Caffeine Level (ug/ml)
Caffeine Trial
SUMMARY
Groups
Pre-Treatment
Post Absorption

Count Sum Average
7
11.653 1.665
7
31.714 4.531

ANOVA
Source o f Variation
Between Groups
Within Groups

SS
28.747
5.164

1
12

Total

33.911

13

MS
28.747
0.430

Variance
0.045
0.815

F
66.805

P-value F crit
3.02E-06 4.747

Table 2: Plasma Caffeine Level - Placebo Trial
Anova: Single Factor
Pre/Post Plasma Caffeine Level (ug/ml)
Placebo Trial
SUMMARY
Groiqjs
Pre-Treatment
Post Absorption

Count Sum Average
7
10.571 1.510
7
12.199 1.743

ANOVA
Source o f Variation
Between Groups
Within Groups

SS
0.189
0.696

df
1
12

Total

0.885

13

MS
0.189
0.058

Variance
0.047
0.069

F
3.267

P-value
0.096
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4.747
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Table 3: Time to Exhaustion

t-Test: Paired Two Sample for Means
Time to Exhaustion (minutes)

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean Difference
df
tStat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Caffeine
12.54
34.39
7.00
0.97
0.00
6.00
0-36
0.37
1.94
0.73
2.45

Placebo
12.31
43.78
7.00

Table 4: Performance bv Work Stages

t-Test: Paired Two Sample for Means
Woik Stages

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean Difference
df
t Stat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Caffeine
4.68
3.75
7.00
0.98
0.00
6.00
0.43
0.34
1.94
0.68
2.45

Placebo
4.59
5.01
7.00
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Table 5: Total Power Output

t-Test: Paired Two Sample for Means
Power Output (Watts)

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean Difference
df
tStat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Caffeine
1661.61
492447.53
7.00
0.98
0.00
6.00
0.44
0.34
1.94
0.67
2.45

Placebo
1630.38
642127.62
7.00

Table 6: Plasma Lactate Concentration

t-Test: Paired Two Sample for Means
Plasma Lactate Concentration (mM)

Mean
Variance
Observations
Pearson Correlation
Hypothesized Mean Difference
df
tS tat
P(T<=t) one-tail
t Critical one-tail
P(T<=t) two-tail
t Critical two-tail

Caffeine
11.33
1.08
6.00
0.23
0.00
5.00
-0.38
0.36
2.02
0.72
2.57

Placebo
11.63
3.55
6.00
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DATE:

October 9, 1996

TO:

James a. Herman
M/S: 3034

FROM:

RE :

(KIN)

^
Lawrence Golding
y*- Chairman, Biomedical Committee of the
Institutional Review Board
Status of Human Subject Protocolentitled:
"Effects of Caffeine on High-Intensity, Intermittent
Exercise to Exhaustion"
OS? #504sl096-090

This memorandum is official notification that the protocol for
the project referenced above has been approved by the Biomedical
Committee of the Institutional Review Board.
This approval is
approved for a period of one year from the date of this
notification and work on the project may proceed.
Should the use of human subjects described in this protocol
continue beyond a year from the date of this notification, it
will be necessary to request an extension.
If you have any questions or require any assistance, please give
us a call at 895-1357.

cc:

Dr. J. Young (KIN-3034)
OSP File

Office of Sponsored Programs
4505 Maryland Parkway • Box 451037 • Las Vegas, Nevada 89154-1037
(702) 895-1357 • FAX (702) 895-4242
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Consent Form for Participation in Research
Exercise Physiology Laboratory
University of Nevada, Las Vegas
Title:
The Effects of Caffeine on High-Intensity, Intermittent Exercise to Exhaustion
Purpose:
O f all the central nervous system stimulants, caffeine is among the most widely used
drugs in the world. Caffeine has been manipulated by athletes in an attempt to enhance
their performance. Most o f the research surrounding the purported effects of caffeine
have focused on caffeine’s influence during endurance exercise. To date, very little
research has focused on high-intensity exercise to exhaustion. Therefore, the purpose of
this study is to examine the effects of caffeine on high-intensity, intermittent exercise.
Procedures:

Participants will report to the exercise physiology lab at least one week prior to the
beginning o f the test protocol. At this time, peak oxygen uptake levels will be measured
during an cycle ergometer exercise protocol. Prior to beginning the exercise protocol, a
one way rebreathing valve will be fitted to the participant to measure respiratory gases.
The warm up period o f the exercise protocol will consist o f the participant cycling for 5
minutes with minimal resistance. At the conclusion o f the warm up period, the
participant will pedal with a resistance o f 50 watts for one minute. An additional 25 watts
o f resistance will be added at the end o f each one minute segment. This will continue
until the participant can not maintain an adequate level o f work. Upon completion o f the
peak oxygen uptake test, participants will be asked to abstain fi'om all caffeine during the
following two weeks in an attempt to obtain the strongest possible effect fiom the
caffeine sample. Caffeine abstinence spanning two weeks is necessary to allow
participants to perform the exercise protocol under caffeine and placebo conditions.
Participants will report to the exercise lab at their assigned time, following a 12 hour
overnight fast. At this time, a small blood sample will be drawn fiom the finger into a
microtubule. Participants will be given a caffeine solution based on body mass or a
placebo and asked to sit for one hour. At the end o f the one hour absorption period, a
second blood sample will be drawn fiom the finger into a microtubule. Afier a 5 minute
warm up period with minimal resistance, the test protocol will begin. Based on results
obtained from the peak oxygen uptake test, the participant will be asked to cycle 80
revolutions per minute for one minute at 120% o f peak oxygen uptake. This period will
be followed by a two minute rest period in which resistance will be reduced to 50 Watts.
At the end of the two minute rest period, the same resistance will be placed on the cycle
and the participant asked to cycle 80 revolutions per minute for one minute. These
work/rest periods will continue until the participant is unable to maintain an adequate
level o f work consistent with the test parameters. At the end o f the test, a third
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micortubule blood sample will be drawn from the participant. A cool down period in
which the participants cardiorespiratory condition will be closely monitored.
The following week will consist o f the same procedure with the exception o f the caffeine
or placebo sample. Participants will receive the alternate supplement during the second
week.

Risks:
Due to the intense level of exercise required for this experiment, participants may
experience some muscle fatigue during the test protocol. Delayed onset muscle soreness
may also develop within 48 hours following the exercise protocol. Abrupt cessation of
caffeine consumption may result in some discomfort. Additionally, some gastrointestinal
discomfort may result from consumption o f caffeine or placebo solutions.

Benefitsi
There are two benefits associated with this experiment. First, the participant will receive
an accurate appraisal o f their peak oxygen uptake capacity (V02 max) based on the
current state o f physical conditioning. Second, the results o f this study will contribute to
the knowledge and understanding o f caffeine and its effect on athletic performance.

All information regarding this experiment will be held in the strictest o f confidence.
Only those people directly involved with this experiment will be permitted access to this
information. If this study is published in a scientific journal or presented at a conference,
names and identities will be altered to protect the confidentiality o f the participants.
Right to refuse or withdraw:

Participation in this study is voluntary. Participants may refuse to sign the consent form
or withdraw from the experiment at any time.

Questions:

Any questions or concerns that may arise can be addressed by Jim Herman at 735-4242
or John Young, Ph D. at 895-4626. Questions regarding participant’s rights during
human subjects research can be answered by the UNLV Office of Sponsored Programs at
895-1357.
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Please read the statement below, and sign and date this form if you agree with the
conditions o f the study.

I have read and understand this form and the content of the test procedure.
Furthermore, I have volunteered for this study o f my own volition. I understand the test
protocol and all o f my questions have been answered to my satisfaction. I acknowledge
that I may withdraw from the study at any time without recrimination.

Participant Name (print)

Signature o f Participant

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Date

APPENDIX n i

CAFFEINE ASSAY

47

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

48
CAFFEINE ASSAY
Principle:
The premise behind this method for caffeine extraction is based on caffeine’s ability to
absorb light at 273 nanometers. Below is a list o f the reagents need to perform this assay.
Also included is a list o f instructions with values reduced for 25 microliter (pi) blood
samples.
Reagents:
NaCl
0.1 Normal (N) NaOH
Benzene
5NHC1
Procédure:
1. Prepare each 2 ml capped ependorf tube with:
18.75 pg NaCl
6.25 pi NaOH
125 pi Benzene
2. Add 25 pi o f serum to a prepared 1.5 ml ependorf tube.
3. Cap and mix by inversion and shake mechanically for 15 minutes.
4. Centrifuge tubes for 15 minutes (1000 x gravity).
5. Transfer 100 pi aliquot o f the upper phase to a tube containing 50 pi o f 5 N HCl.
6. Cap tubes and shake mechanically for 5 minutes.
7. Suction the benzene layer from the contents o f the tube.
8. Transfer 37.5 to 40 pi o f the aqueous phase to a quartz micro cuvette and read in a
spectrophotometer calibrated against a water blank at 273 nanometers.
9. Plot results on a regression line constructed from serial dilution samples o f known
concentration (5 pg/ml to 20 pg/ml).
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Normal Values
Five milligrams o f caffeine per kilogram body weight in 250 ml solution will
result in plasma caffeine levels o f 3.5 to 9.4 /zg/ml one hour later (Axelrod &
Reichenthal, 1953).

Reference:
Axelrod, J., & Reichenthal. J. (1953). The fate o f caffeine in man and a method
for its estimation in biological material. Journal of Pharmacology and Fxperimental
Therapeutics, 107, 519-523.
Routh, J., Shane, N., Aredondo, E., & Paul, W. (1969). Determination o f caffeine
in serum and urine. Clinical Chemistry, 15, 661-668.
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Participant 1
Age (years)...................................................27
Weight (kg) .................................................89
V 02 (max-kg-BW)...................................... 43
Caffeine Trial
Baseline Caffeine (pg/m l)..................... 1.66
Peak Caffeine (pg/m l)...........................4.09
Placebo Trial
Baseline Caffeine (pg/m l)..................... 1.72
Peak Caffeine (pg/m l)........................... 1.97
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 12.00
Placebo Trial ..................................... ........
Time to Exhaustion (minutes)
Caffeine Trial ..................................... 12.85
Placebo T ria l....................................... 12.60
Total Power Output (Watts)
Caffeine Trial .......................................1892
Placebo T ria l.........................................1794

Participant 2
Age (years)...................................................25
Weight (kg) .................................................65
V 02 (m axkg'B W )...................................... 60
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.38
Peak Caffeine (pg/m l)...........................5.61
Placebo Trial
Baseline Caffeine (pg/m l).....................1.27
Peak Caffeine (pg/m l)........................... 1.35
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 10.30
Placebo Trial ..................................... 11.70
Time to Exhaustion (minutes)
Caffeine Trial .......................................6.75
Placebo T ria l.........................................6.88
Total Power Output (Watts)
Caffeine Trial .......................................1073
Placebo T ria l....................................... 1124
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Participant 3
Age (years)...................................................25
Weight (kg) .................................................71
V 02 (m axkg'B W ).......................................45
Caffeine Trial
Baseline Caffeine (pg/m l)..................... 1.52
Peak Caffeine (pg/m l)...........................5.79
Placebo Trial
Baseline Caffeine (pg/m l).....................1.54
Peak Caffeine (pg/m l)........................... 1.79
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 12.60
Placebo Trial ..................................... 10.60
Time to Exhaustion (minutes)
Caffeine Trial ....................................... 8.45
Placebo T ria l......................................... 6.77
Total Power Output (Watts)
Caffeine Trial .......................................1139
Placebo T ria l..........................................913

Age (years)...................................................29
W e i^ t (kg) .................................................78
V 02 (m ax'kg'BW )...................................... 55
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.69
Peak Caffeine (pg/m l)...........................4.25
Placebo Trial
Baseline Caffeine (pg/m l).....................1.47
Peak Caffeine (pg/m l)...........................1.59
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 12.40
Placebo Trial ..................................... 15.20
Time to Exhaustion (minutes)
Caffeine Trial ......................................24.63
Placebo T ria l....................................... 24.98
Total Power Output (Watts)
Caffeine Trial ...................................... 3108
Placebo T ria l........................................ 3234

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

53

Participants
Age (years)................................................... 23
Weight (kg) ................................................. 72
V 02 (m axkg'B W )...................................... 46
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.81
Peak Caffeine (pg/m l)...........................3.26
Placebo Trial
Baseline Caffeine (pg/m l).....................1.28
Peak Caffeine (p g /m l)........................... 1.60
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 10.30
Placebo Trial ..................................... 11.40
Time to Exhaustion (minutes)
Caffeine Trial ..................................... 12.93
Placebo T ria l....................................... 15.75
Total Power Output (Watts)
Caffeine Trial ....................................... 1628
Placebo T ria l......................................... 1898

Age (years)................................................... 25
W ei^ t (kg) ................................................. 75
V02 (m axkg'B W )...................................... 42
Caffeine Trial
Baseline Caffeine (pg/m l).....................1.56
Peak Caffeine (p g /m l).......................... 4.69
Placebo Trial
Baseline Caffeine (pg/m l).....................1.85
Peak Caffeine (pg/m l).......................... 2.15
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 10.70
Placebo Trial ..................................... 11.20
Time to Exhaustion (minutes)
Caffeine Trial ..................................... 12.70
Placebo T ria l....................................... 12.33
Total Power Output (Watts)
Caffeine Trial .......................................1551
Placebo T ria l......................................... 1430
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Participant 7
Age (years)....................................................27
Weight (kg) ..................................................94
V02 (max-kg-BW)....................................... 40
Caffeine Trial
Baseline Caffeine (p g /m l).................... 2.03
Peak Caffeine (p g /m l)...........................4.03
Placebo Trial
Baseline Caffeine (p g /m l).....................1.43
Peak Caffeine (p g /m l)........................... 1.75
Lactate Concentration (mM/L)
Caffeine Trial ..................................... 11.70
Placebo Trial ........................................9.70
Time to Exhaustion (minutes)
Caffeine Trial ........................................9.45
Placebo T r ia l..........................................6.83
Total Power Output (Watts)
Caffeine Trial ........................................1242
Placebo T r ia l......................................... 1020
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